KR20090082221A - 유기 화합물 - Google Patents

유기 화합물 Download PDF

Info

Publication number
KR20090082221A
KR20090082221A KR1020097009957A KR20097009957A KR20090082221A KR 20090082221 A KR20090082221 A KR 20090082221A KR 1020097009957 A KR1020097009957 A KR 1020097009957A KR 20097009957 A KR20097009957 A KR 20097009957A KR 20090082221 A KR20090082221 A KR 20090082221A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
substituted
het
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097009957A
Other languages
English (en)
Korean (ko)
Inventor
래리 알렉산더 가이터
바딤 이오우르겐코
마크 애론 래보우
데일 앨런 포터
크리스토퍼 션 스트라우브
야오 야오
레이 자웰
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20090082221A publication Critical patent/KR20090082221A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020097009957A 2006-10-19 2007-10-17 유기 화합물 Withdrawn KR20090082221A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86215506P 2006-10-19 2006-10-19
US86216106P 2006-10-19 2006-10-19
US60/862,161 2006-10-19
US60/862,155 2006-10-19

Publications (1)

Publication Number Publication Date
KR20090082221A true KR20090082221A (ko) 2009-07-29

Family

ID=39364966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097009957A Withdrawn KR20090082221A (ko) 2006-10-19 2007-10-17 유기 화합물

Country Status (10)

Country Link
US (1) US20100316573A1 (cg-RX-API-DMAC7.html)
EP (1) EP2076778A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010507096A (cg-RX-API-DMAC7.html)
KR (1) KR20090082221A (cg-RX-API-DMAC7.html)
AU (1) AU2007318220A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0717411A2 (cg-RX-API-DMAC7.html)
CA (1) CA2665838A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009004061A (cg-RX-API-DMAC7.html)
RU (1) RU2009118487A (cg-RX-API-DMAC7.html)
WO (1) WO2008057172A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200055254A (ko) * 2018-11-13 2020-05-21 국민대학교산학협력단 퀴논계 화합물을 유효성분으로 포함하는 피부 미백용 조성물 및 그 화합물의 스크리닝 방법

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Iap結合性化合物
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
US20090005411A1 (en) * 2005-12-20 2009-01-01 Novartic Ag Combinations of Organic Compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Iap阻害剤
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
EP2296650B1 (en) * 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
JP2013505446A (ja) * 2009-09-18 2013-02-14 ノバルティス アーゲー Iap阻害剤化合物のためのバイオマーカー
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
KR20150011822A (ko) 2012-05-04 2015-02-02 노파르티스 아게 Iap 억제제 요법을 위한 바이오마커
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1933847A (zh) * 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200055254A (ko) * 2018-11-13 2020-05-21 국민대학교산학협력단 퀴논계 화합물을 유효성분으로 포함하는 피부 미백용 조성물 및 그 화합물의 스크리닝 방법

Also Published As

Publication number Publication date
US20100316573A1 (en) 2010-12-16
JP2010507096A (ja) 2010-03-04
AU2007318220A1 (en) 2008-05-15
EP2076778A2 (en) 2009-07-08
WO2008057172A2 (en) 2008-05-15
BRPI0717411A2 (pt) 2013-11-12
RU2009118487A (ru) 2010-11-27
WO2008057172A3 (en) 2008-09-12
MX2009004061A (es) 2009-04-27
CA2665838A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
US20100316573A1 (en) Organic Compounds
Uddin et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells
JP5227805B2 (ja) Iap阻害剤とタキサン7の組合せ剤
KR20260074308A (ko) 필라델피아 염색체 양성 혈액암의 치료에 사용하기 위한 sos1 억제제
US20050014783A1 (en) Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
JP2014508720A (ja) 癌からの転移を阻害する方法
US12011436B2 (en) Use of NOX inhibitors for treatment of cancer
KR20090083412A (ko) 급성 골수성 백혈병의 치료를 위한 iap 억제제의 용도
JP2023514717A (ja) エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
Rossi et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib
ES2397830T3 (es) Uso de imatinib para tratar trastornos hepáticos e infecciones virales
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
KR100392573B1 (ko) 암 치료용 HMG CoA 환원효소와 조합한 화합물
US20120196793A1 (en) Biomarkers for iap inhibitor compounds
WO2016198698A2 (en) P38 inhibitors for the treatment and prophylaxis of liver cancer
KR101335458B1 (ko) 백혈병 치료용 약학조성물
US12331045B2 (en) Substituted phenyl oxazolone compounds
CN101529254A (zh) 有机化合物
WO2024249540A1 (en) Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
KR101276425B1 (ko) 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물
WO2024263853A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
US20050042283A1 (en) Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
WO2024254227A1 (en) Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
US20220340665A1 (en) Inhibitor against expression of immune checkpoint molecule

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000